NEUROCRINE BIOSCIENCES INC (NBIX)

US64125C1099 - Common Stock

133.295  +0.98 (+0.74%)

Fundamental Rating

8

Taking everything into account, NBIX scores 8 out of 10 in our fundamental rating. NBIX was compared to 599 industry peers in the Biotechnology industry. NBIX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. NBIX is evaluated to be cheap and growing strongly. This does not happen too often! This makes NBIX very considerable for value and growth and quality investing!



9

1. Profitability

1.1 Basic Checks

In the past year NBIX was profitable.
In the past year NBIX had a positive cash flow from operations.
Each year in the past 5 years NBIX has been profitable.
In the past 5 years NBIX always reported a positive cash flow from operatings.

1.2 Ratios

NBIX's Return On Assets of 7.68% is amongst the best of the industry. NBIX outperforms 96.28% of its industry peers.
NBIX's Return On Equity of 11.19% is amongst the best of the industry. NBIX outperforms 96.11% of its industry peers.
NBIX's Return On Invested Capital of 11.21% is amongst the best of the industry. NBIX outperforms 96.62% of its industry peers.
NBIX had an Average Return On Invested Capital over the past 3 years of 9.89%. This is below the industry average of 13.52%.
The last Return On Invested Capital (11.21%) for NBIX is above the 3 year average (9.89%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.68%
ROE 11.19%
ROIC 11.21%
ROA(3y)6.18%
ROA(5y)8.97%
ROE(3y)8.92%
ROE(5y)13.75%
ROIC(3y)9.89%
ROIC(5y)11.96%

1.3 Margins

The Profit Margin of NBIX (13.23%) is better than 96.62% of its industry peers.
NBIX's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 20.92%, NBIX belongs to the best of the industry, outperforming 97.13% of the companies in the same industry.
In the last couple of years the Operating Margin of NBIX has grown nicely.
NBIX has a better Gross Margin (97.90%) than 97.64% of its industry peers.
NBIX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 20.92%
PM (TTM) 13.23%
GM 97.9%
OM growth 3Y-12.58%
OM growth 5Y20.67%
PM growth 3Y-30.22%
PM growth 5Y23.12%
GM growth 3Y-0.38%
GM growth 5Y-0.21%

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), NBIX is creating some value.
Compared to 1 year ago, NBIX has more shares outstanding
Compared to 5 years ago, NBIX has more shares outstanding
The debt/assets ratio for NBIX has been reduced compared to a year ago.

2.2 Solvency

An Altman-Z score of 8.92 indicates that NBIX is not in any danger for bankruptcy at the moment.
NBIX's Altman-Z score of 8.92 is amongst the best of the industry. NBIX outperforms 83.11% of its industry peers.
NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.47
Altman-Z 8.92
ROIC/WACC1.03
WACC10.91%

2.3 Liquidity

A Current Ratio of 2.45 indicates that NBIX has no problem at all paying its short term obligations.
The Current ratio of NBIX (2.45) is worse than 75.17% of its industry peers.
NBIX has a Quick Ratio of 2.40. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.
NBIX has a Quick ratio of 2.40. This is in the lower half of the industry: NBIX underperforms 74.32% of its industry peers.
Industry RankSector Rank
Current Ratio 2.45
Quick Ratio 2.4

9

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 58.17% over the past year.
The Earnings Per Share has been growing by 70.09% on average over the past years. This is a very strong growth
The Revenue has grown by 26.76% in the past year. This is a very strong growth!
NBIX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 33.13% yearly.
EPS 1Y (TTM)58.17%
EPS 3Y23.01%
EPS 5Y70.09%
EPS growth Q2Q63.64%
Revenue 1Y (TTM)26.76%
Revenue growth 3Y21.74%
Revenue growth 5Y33.13%
Revenue growth Q2Q25.05%

3.2 Future

NBIX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 42.64% yearly.
The Revenue is expected to grow by 13.87% on average over the next years. This is quite good.
EPS Next Y95.73%
EPS Next 2Y63.4%
EPS Next 3Y62.72%
EPS Next 5Y42.64%
Revenue Next Year14.79%
Revenue Next 2Y14.4%
Revenue Next 3Y15.08%
Revenue Next 5Y13.87%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

7

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 55.08 indicates a quite expensive valuation of NBIX.
Based on the Price/Earnings ratio, NBIX is valued cheaper than 94.59% of the companies in the same industry.
NBIX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.18.
NBIX is valuated quite expensively with a Price/Forward Earnings ratio of 28.14.
95.44% of the companies in the same industry are more expensive than NBIX, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 21.51. NBIX is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE 55.08
Fwd PE 28.14

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, NBIX is valued cheaply inside the industry as 94.43% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, NBIX is valued cheaper than 95.61% of the companies in the same industry.
Industry RankSector Rank
P/FCF 36.22
EV/EBITDA 25.42

4.3 Compensation for Growth

NBIX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NBIX has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as NBIX's earnings are expected to grow with 62.72% in the coming years.
PEG (NY)0.58
PEG (5Y)0.79
EPS Next 2Y63.4%
EPS Next 3Y62.72%

0

5. Dividend

5.1 Amount

No dividends for NBIX!.
Industry RankSector Rank
Dividend Yield N/A

NEUROCRINE BIOSCIENCES INC

NASDAQ:NBIX (2/20/2024, 9:27:46 AM)

133.295

+0.98 (+0.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap13.10B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 55.08
Fwd PE 28.14
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.58
PEG (5Y)0.79
Profitability
Industry RankSector Rank
ROA 7.68%
ROE 11.19%
ROCE
ROIC
ROICexc
ROICexgc
OM 20.92%
PM (TTM) 13.23%
GM 97.9%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.45
Quick Ratio 2.4
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)58.17%
EPS 3Y23.01%
EPS 5Y
EPS growth Q2Q
EPS Next Y95.73%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)26.76%
Revenue growth 3Y21.74%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y